Mr. Rashid Ahmed Bux reports

BIOMARK SECURES KEY PATENTS IN ASIA'S LARGEST MARKETS FOR EARLY LUNG CANCER LIQUID BIOPSY

Biomark Diagnostics Inc. has received the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer.

The newly granted Chinese patent (N degree ZL 201980092723.X) and Japanese patent (N degree 2023-111262) cover Biomark's technology for detecting lung cancer by measuring specific metabolite Biomarkers. In a recent study published in the International Journal of Molecular Sciences, Biomark's patented platform has shown a market-leading sensitivity of over 90 per cent for early stage lung cancer. This capability empowers clinicians to deliver fast, actionable results that can significantly improve patient outcomes.

"Securing these patents in two of Asia's largest health care markets is a transformational milestone for Biomark," said Rashid Ahmed Bux, president and chief executive officer of Biomark. "Our technology is directly aligned with the next wave of liquid biopsy adoption across the region. These patents not only strengthen our global IP estate but also position us to capture significant commercial and clinical leadership, opening up new opportunities for expansion, technology licensing and strategic partnerships."

Granting of these strategic intellectual properties comes as Asia's major markets, China and Japan, face high and rising lung cancer rates. The liquid biopsy market in China is forecast to surpass $670-million (U.S.) by 2030, while Japan is projected to reach over $912-million (U.S.) by the same year, both with robust double-digit growth. National screening policies and an expanding commitment to advanced diagnostics are driving this rapid adoption.

About Biomark Diagnostics Inc.

Biomark Diagnostics is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated Biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.